AX-2026-041671

PT-141 (Bremelanotide) · 10 mg declared · Flourishglobal Peptide Biotech (Chengdu) Co., Ltd. · lot FGP-2602-Y8741

PASSPURITY ONLY

Report ID: AX-2026-041671
Compound: PT-141 (Bremelanotide)
Compound class: Melanocortin-receptor peptides
Supplier: FGP — Flourishglobal Peptide Biotech (Chengdu) Co., Ltd.
Batch / lot: FGP-2602-Y8741
Declared label claim: 10mg
Laboratory: PeptideMeter
Assay date: 29 Apr 2026
Submitted: 10 May 2026
Quarter: 2026-Q2
Submitter: a.girard
Sample provenance: Buyer-sourced

Section 1

Results

Measured against the index acceptance specification for the melanocortin-receptor peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 28 min gradient, 214 nm	99.42	% area	≥ 98.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.58	% area	≤ 1.5	PASS
Largest single impurity	RP-HPLC — des-acetyl (−42 Da)	0.40	% area	≤ 1.00	PASS
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	3.99	%	≤ 8.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	5.00	%	≤ 10.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.43	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	membrane filtration, USP <71>, 14 d	No growth at 14 d	—	no growth	PASS
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Visible particulates, did not clear	—	clear, no visible particulates	FAIL
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.18	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 28 min gradient	8.89	min	8.94 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	0.93	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	55,172	—	≥ 20,000	PASS
Resolution to nearest impurity	vs melanotan II (C-terminal amide, −1 Da)	1.92	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 28 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 55,172, and skew follows the reported asymmetry factor of 0.93. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.40 % impurity against a 99.42 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	PT-141 (Bremelanotide) — main peak	8.89	4,832,120	99.42	—
2	des-acetyl (−42 Da)	8.46	19,441	0.40	-42.011
3	linear precursor (+18 Da)	8.24	3,888	0.08	+18.011
4	oxidised Trp (+16 Da)	8.57	2,916	0.06	+15.995
5	melanotan II (C-terminal amide, −1 Da)	9.19	1,944	0.04	-0.984
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.72	99.42	divergence +0.07 pp vs batch median
Total impurities (% area)	0.28	0.58
Largest single impurity (% area)	0.14	0.40
Water (%)	3.6	3.99
Counter-ion (%)	9.2	5.00
Peptide content (%w/w)	86.6	not determined
Endotoxin (EU/mg)	0.30	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (2–8 °C, 33 d) → laboratory (courier, ambient, 7 d) → assay.
Assay date: 29 Apr 2026
Submitted to the index: 10 May 2026
Laboratory: PeptideMeter, Tallinn, Estonia
Method basis: 28 min gradient · high-resolution MS
Verification status: PURITY ONLY

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

prep_hplc_cut10 May 2026

0.58 % total impurities on PT-141 (Bremelanotide) means the preparative fraction was cut narrow. That trades yield for purity, and the trade was made in the buyer's favour on this lot.

selection_bias10 May 2026

Provenance handles supplier selection. It does not handle submitter selection, which is the larger confounder and the one the index cannot measure.

endotoxin_limit10 May 2026

Heat-stable, filter-passing, and invisible to every method on this record. Those three properties together are why the omission matters more than it looks.

Section 7

Related records

Same batch — lot FGP-2602-Y8741 n=10

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041662	FGP-2602-Y8741	Nordanalyt	2026-Q2	99.86	4.58	—	Buyer-sourced	0	PASS
AX-2026-041663	FGP-2602-Y8741	Janoshik	2026-Q2	99.33	4.04	91.4	Buyer-sourced	0	PASS
AX-2026-041664	FGP-2602-Y8741	Janoshik	2026-Q2	99.90	4.48	106.5	Buyer-sourced	0	PASS
AX-2026-041665	FGP-2602-Y8741	Nordanalyt	2026-Q2	99.51	3.89	91.3	Buyer-sourced	0	PASS
AX-2026-041666	FGP-2602-Y8741	Janoshik	2026-Q2	99.93	4.57	88.6	Buyer-sourced	1	MARGINAL
AX-2026-041667	FGP-2602-Y8741	Janoshik	2026-Q2	99.78	4.78	94.0	Buyer-sourced	0	PASS
AX-2026-041668	FGP-2602-Y8741	PeptideMeter	2026-Q2	99.59	4.86	—	Buyer-sourced	0	PASS
AX-2026-041669	FGP-2602-Y8741	Janoshik	2026-Q2	99.39	4.82	—	Buyer-sourced	0	PASS
AX-2026-041670	FGP-2602-Y8741	Janoshik	2026-Q2	99.70	4.27	106.9	Buyer-sourced	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

All PT-141 (Bremelanotide) records n=152
All FGP records n=200
All PeptideMeter records n=1116
All 2026-Q2 records n=1126
PT-141 (Bremelanotide) by supplier
PT-141 (Bremelanotide) impurity profile

Other recent PT-141 (Bremelanotide) records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041471	QYB	QYB-2607-L4875	Janoshik	2026-Q3	99.72	3.75	101.7	Buyer-sourced	0	PASS
AX-2026-041473	QYB	QYB-2607-L4875	PeptideMeter	2026-Q3	99.58	3.74	94.4	Buyer-sourced	0	PASS
AX-2026-041472	QYB	QYB-2607-L4875	PeptideMeter	2026-Q3	99.93	3.94	—	Buyer-sourced	0	PASS
AX-2026-041474	QYB	QYB-2607-L4875	VendorInvestigate	2026-Q3	99.16	3.78	95.6	Buyer-sourced	0	PASS
AX-2026-041470	QYB	QYB-2607-L4875	Janoshik	2026-Q3	99.77	4.10	—	Buyer-sourced	0	PASS
AX-2026-042139	JEEP	JEEP-2601-K8195	VendorInvestigate	2026-Q2	98.32	4.29	99.4	Buyer-sourced	1	FAIL
AX-2026-041964	AMB	AMB-2601-M5602	Janoshik	2026-Q2	99.93	3.20	—	Buyer-sourced	0	PASS
AX-2026-041664	FGP	FGP-2602-Y8741	Janoshik	2026-Q2	99.90	4.48	106.5	Buyer-sourced	0	PASS

Other recent FGP records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-041643	Semaglutide	FGP-2602-M8547	Janoshik	2026-Q3	99.31	2.79	100.7	Buyer-sourced	PASS
AX-2026-041638	Semaglutide	FGP-2602-M8547	Janoshik	2026-Q3	99.40	2.75	105.8	Buyer-sourced	PASS
AX-2026-041641	Semaglutide	FGP-2602-M8547	PeptideMeter	2026-Q3	98.98	2.38	105.0	Buyer-sourced	PASS
AX-2026-041610	Tirzepatide	FGP-2603-L7753	Janoshik	2026-Q3	98.81	2.45	101.0	Buyer-sourced	PASS
AX-2026-041637	Semaglutide	FGP-2602-M8547	PeptideMeter	2026-Q3	99.40	2.83	—	Laboratory-retained	PASS
AX-2026-041642	Semaglutide	FGP-2602-M8547	PeptideMeter	2026-Q3	98.78	2.24	—	Buyer-sourced	PASS
AX-2026-041609	Tirzepatide	FGP-2603-L7753	Janoshik	2026-Q3	98.52	2.00	98.0	Buyer-sourced	PASS
AX-2026-041636	Semaglutide	FGP-2602-M8547	Nordanalyt	2026-Q3	99.39	2.17	—	Buyer-sourced	PASS